.png){kind=logo}
Gabify has raised $175,000 to develop AI-powered tools for early diagnosis. The startup is aimed to improve healthcare outcomes through faster and more accurate disease detection. The company estimates a global opportunity of $110 billion, with a growing need for solutions that can bridge the gap between demand and available care.
Gabify’s pre-seed funding is led by Inflection Point Ventures to build AI tools for early diagnosis and therapy of neurodevelopmental disorders in children. The startup has also secured Rs. 25 lakh under the Nidhi Seed Support Scheme from GHRTBI.
The funding will go into clinical validation, product development, and team expansion as the company looks to move from early deployments to a more scalable model.
Ankur Mittal, Co-founder, Inflection Point Ventures, said, “Addressing neurodevelopmental challenges at an early stage plays a critical role in shaping a child’s future, yet it remains one of the most underserved areas in the healthcare ecosystem. Gabify is tackling this gap through a strong blend of clinical validation and AI led innovation, enabling faster and more accurate identification of developmental conditions.”
Identifying speech and neurodevelopmental conditions like autism or ADHD takes a longer time. Limited access to specialists and fragmented processes make early intervention difficult. Gabify is trying to address this with an AI-led platform that combines screening and therapy management.
Founded in 2023, Gabify is building an AI-based platform for early screening and therapy management of speech and neurodevelopmental disorders. The system combines voice and vision-based AI to analyse speech patterns, facial expressions, eye movement, and behavioural indicators across more than 189 clinically validated parameters aligned with global diagnostic frameworks.
The platform also uses a human-in-the-loop approach, where clinical experts review AI-generated outputs to ensure accuracy and reliability in assessments. The company said its system can reduce assessment time by up to 70 percent, allowing clinicians to serve more patients while maintaining clinical standards.
Gabify’s platform has already been tested across more than 35 preschool and daycare centres in India during its private beta phase.
Also Read: AI in Healthcare: Applications, Benefits, Use Cases, and Future Trends
Gabify’s platform follows a human-in-the-loop (HITL) model, where AI-generated outputs are reviewed by clinical experts before being finalised. In this way, the Gabify system supports professional judgement.
Gabify's focus is on strengthening its clinical foundation and expanding adoption. The company plans to scale through a mix of B2B, B2C, and CSR-led deployments, with a goal of impacting one million children by 2028.
Sahil Chopra, Founder and Chief Executive Officer, Gabify, said, “Our goal with Gabify is to ensure that no child is left behind simply due to delayed diagnosis or lack of access. We are building technology that supports clinicians, assists parents, and improves early intervention outcomes.”
